Annovis Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY September 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — |
| Operating income | -$29.7M | -$26.7M | -$45.0M | -$25.5M | — |
| Operating expenses | $29.7M | $26.7M | $45.0M | $25.5M | — |
| Cash from operations | -$25.6M | -$21.9M | -$40.0M | -$17.3M | — |
| Total assets | $21.1M | $13.9M | $10.2M | $36.0M | $37.1M |
| Total liabilities | $4.2M | $4.6M | $18.0M | $7.7M | $2.5M |
Shares outstanding 34.6M · Free float 85.5%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.